IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology

Stock Information for Trevena Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Trevena Inc.

IVERIC bio to Participate in Upcoming September Investor / Industry Conferences
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results
IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.